Literature DB >> 18228584

Preformulation studies of Clostridium difficile toxoids A and B.

Maya S Salnikova1, Sangeeta B Joshi, J Howard Rytting, Michel Warny, C Russell Middaugh.   

Abstract

To enhance the physical stability of Clostridium difficile toxoids A and B, screening for stabilizing compounds was performed. The screening of 30 GRAS compounds at various concentrations and in several combinations was performed in two parts. First, a high-throughput aggregation assay was used to screen for compounds which delayed or prevented aggregation of toxoids under stress conditions (toxoids at pH 5-5.5 were incubated at 55 degrees C for 55 or 75 min). Compounds which stabilized both proteins were further studied for their ability to delay unfolding under conditions leading to a presumably native-like folded state (pH 6.5). The thermal stability of the toxoids on the surface of Alhydrogel was monitored with DSC and also showed significant improvement in the presence of certain excipients. This study has generated information concerning the free and adjuvant bound toxoids behavior under a range of conditions (temperature, solutes) that can be used to design pharmaceutical formulations of enhanced physical stability. (c) 2008 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18228584     DOI: 10.1002/jps.21300

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

Review 1.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 2.  A rational, systematic approach for the development of vaccine formulations.

Authors:  Garry L Morefield
Journal:  AAPS J       Date:  2011-02-23       Impact factor: 4.009

3.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

4.  Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease.

Authors:  Chandrabali Ghose; Janneke M Verhagen; Xinhua Chen; Jian Yu; Yaoxing Huang; Olivia Chenesseau; Ciarán P Kelly; David D Ho
Journal:  Infect Immun       Date:  2013-04-01       Impact factor: 3.441

5.  A systematic approach toward stabilization of CagL, a protein antigen from Helicobacter pylori that is a candidate subunit vaccine.

Authors:  Shyamal P Choudhari; Kirk P Pendleton; Joshua D Ramsey; Thomas G Blanchard; William D Picking
Journal:  J Pharm Sci       Date:  2013-06-21       Impact factor: 3.534

Review 6.  Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability.

Authors:  Tanya Clapp; Paul Siebert; Dexiang Chen; LaToya Jones Braun
Journal:  J Pharm Sci       Date:  2010-08-25       Impact factor: 3.534

Review 7.  Clostridium difficile infection in the twenty-first century.

Authors:  Chandrabali Ghose
Journal:  Emerg Microbes Infect       Date:  2013-09-18       Impact factor: 7.163

8.  Conformational and thermal stability improvements for the large-scale production of yeast-derived rabbit hemorrhagic disease virus-like particles as multipurpose vaccine.

Authors:  Erlinda Fernández; Jorge R Toledo; Lídice Méndez; Nemecio González; Francisco Parra; José M Martín-Alonso; Miladys Limonta; Kosara Sánchez; Ania Cabrales; Mario P Estrada; Alina Rodríguez-Mallón; Omar Farnós
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.